자궁내막증 치료 시장 규모, 점유율, 성장 및 세계 산업 분석 : 유형별, 용도별, 지역별 인사이트와 예측(2026-2034년)

Growth Factors of endometriosis treatment Market

The global endometriosis treatment market is witnessing steady expansion, driven by increasing disease awareness, rising diagnosis rates, and growing demand for advanced therapeutic solutions among women of reproductive age. Endometriosis is a chronic gynecological condition associated with pelvic pain, infertility, and reduced quality of life, creating a significant need for long-term and effective treatment options. According to Fortune Business Insights, the global endometriosis treatment market was valued at USD 2.39 billion in 2025, reflecting the growing clinical and commercial importance of this therapeutic area.

Market Size and Forecast

In 2026, the market is projected to grow to USD 2.58 billion, supported by improved diagnostic infrastructure, increasing access to specialty care, and the introduction of innovative drug therapies. Over the forecast period, the market is expected to expand significantly and reach USD 5.03 billion by 2034, registering a CAGR of 8.70%.

North America dominated the global market in 2025, accounting for a 49.60% market share, owing to high disease awareness, strong reimbursement frameworks, and the presence of leading pharmaceutical companies.

Market Drivers

A major driver of the endometriosis treatment market is the increasing demand for innovative and disease-modifying treatment alternatives. Traditional therapies rely heavily on hormonal suppression, which often results in adverse effects such as bone density loss, mood changes, and fertility concerns. These limitations have created strong demand for safer, non-hormonal, and targeted therapies that address inflammation, immune dysfunction, and lesion growth.

Pharmaceutical companies are actively investing in research and development to address these unmet needs. For example, in January 2025, Celmatix Therapeutics launched a drug development program for a novel JNK inhibitor targeting pain and inflammation in endometriosis, highlighting the industry's shift toward innovation.

Market Restraints

Despite positive growth trends, high treatment costs remain a key restraint. Advanced therapies such as oral GnRH antagonists are significantly more expensive than generic hormonal treatments, limiting accessibility for patients without adequate insurance coverage. High out-of-pocket costs often result in non-adherence or treatment discontinuation.

For instance, the list price of Orilissa was reported at USD 1,046.66 per dose, illustrating the affordability challenges faced by patients and healthcare systems.

Market Opportunities

Rising investments in research and development present lucrative growth opportunities for the market. With current first-line treatments offering limited relief, pharmaceutical companies are focusing on developing novel therapies with improved safety and long-term efficacy.

In January 2025, Gesynta Pharma AB secured USD 28.7 million in Series B funding to advance a Phase II clinical trial for Vipoglanstat, a promising drug candidate for endometriosis. Such investments are expected to accelerate product pipelines and support future market expansion.

Market Trends

A prominent trend in the market is the expansion of awareness campaigns and patient support initiatives. These efforts promote early diagnosis, reduce stigma around menstrual pain, and educate both patients and clinicians.

For example, in March 2025, the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG) organized Endometriosis Awareness Month 2025, contributing to increased diagnosis rates and treatment adoption globally.

Market Challenges

Patent infringement and legal disputes pose a critical challenge to market growth. Patent-related litigation can reduce exclusivity periods for innovative drugs, enabling early entry of generics and causing revenue erosion.

In May 2025, AbbVie Inc. filed a patent infringement lawsuit against Hetero Labs Ltd. concerning Orilissa, highlighting the legal risks faced by innovators in this space.

Segmentation Analysis

By drug, the others segment dominates the market due to widespread use of older, cost-effective therapies. Orilissa held an 11.18% market share in 2026, while Myfembree/Ryeqo is expected to grow at a strong CAGR due to recent approvals.

By drug class, GnRH antagonists dominated in 2025 and accounted for 40.17% market share in 2026, driven by faster action and improved safety profiles.

By route of administration, the oral segment dominated with a 65.46% share in 2026, supported by high patient adherence and convenience.

By distribution channel, drug stores and retail pharmacies led the market, holding 59.20% share in 2026.

Regional Outlook

North America led the market with USD 1.19 billion in 2025 and USD 1.28 billion in 2026, driven by strong healthcare infrastructure and rising prevalence.

Europe recorded USD 0.56 billion in 2025, while Asia Pacific reached USD 0.46 billion in 2025, supported by growing awareness in China and India.

Latin America and Middle East & Africa showed moderate growth, with valuations of USD 0.09 billion and USD 0.05 billion respectively in 2025.

Competitive Landscape

The market is semi-consolidated, with key players including AbbVie Inc., Pfizer Inc., Bayer AG, AstraZeneca, and Organon. These companies maintain leadership through strong pipelines, global distribution networks, and continuous R&D investments.

Conclusion

The global endometriosis treatment market is poised for strong growth, expanding from USD 2.39 billion in 2025 to USD 5.03 billion by 2034, driven by rising disease awareness, improved diagnostics, and increasing demand for innovative therapies. While high treatment costs and patent-related challenges may limit adoption, growing R&D investments, non-hormonal drug development, and expanding awareness initiatives are expected to create sustainable growth opportunities. Overall, the market is set to evolve significantly, offering improved treatment outcomes and long-term management solutions for women affected by endometriosis worldwide.

Segmentation By Drug, Drug Class, Route of Administration, Distribution Channel, and Region

By Drug * Orilissa

• Myfembree/Ryeqo
• Others

By Drug Class * GnRH Antagonists

• GnRH Agonists
• Others

By Route of Administration * Oral

• Others

By Distribution Channel * Hospital Pharmacies

• Retail Pharmacies
• Online Pharmacies

By Geography * North America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country)

• U.S.
• Canada
• Europe (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Drug, Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Regulatory Scenarios, By Key Countries/Regions
• 4.2. Pipeline Analysis, By Key Players
• 4.3. Epidemiology- Endometriosis, By Key Countries/ Regions
• 4.4. Key Industry Developments (Mergers, Acquisitions, Partnerships, Launches, etc.)

5. Global Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Drug
  • 5.1.1. Orilissa
  • 5.1.2. Myfembree/Ryeqo
  • 5.1.3. Others
• 5.2. Market Analysis, Insights and Forecast - By Drug Class
  • 5.2.1. GnRH Antagonists
  • 5.2.2. GnRH Agonists
  • 5.2.3. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Oral
  • 5.3.2. Others
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Drug
  • 6.1.1. Orilissa
  • 6.1.2. Myfembree/Ryeqo
  • 6.1.3. Others
• 6.2. Market Analysis, Insights and Forecast - By Drug Class
  • 6.2.1. GnRH Antagonists
  • 6.2.2. GnRH Agonists
  • 6.2.3. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Oral
  • 6.3.2. Others
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Drug
  • 7.1.1. ORILISSA
  • 7.1.2. MYFEMBREE/RYEQO
  • 7.1.3. Others
• 7.2. Market Analysis, Insights and Forecast - By Drug Class
  • 7.2.1. GnRH Antagonists
  • 7.2.2. GnRH Agonists
  • 7.2.3. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Oral
  • 7.3.2. Others
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Drug
  • 8.1.1. Orilissa
  • 8.1.2. Myfembree/Ryeqo
  • 8.1.3. Others
• 8.2. Market Analysis, Insights and Forecast - By Drug Class
  • 8.2.1. GnRH Antagonists
  • 8.2.2. GnRH Agonists
  • 8.2.3. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Oral
  • 8.3.2. Others
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Southeast Asia
  • 8.5.5. Australia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Drug
  • 9.1.1. Orilissa
  • 9.1.2. Myfembree/Ryeqo
  • 9.1.3. Others
• 9.2. Market Analysis, Insights and Forecast - By Drug Class
  • 9.2.1. GnRH Antagonists
  • 9.2.2. GnRH Agonists
  • 9.2.3. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Oral
  • 9.3.2. Others
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Endometriosis Treatment Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Drug
  • 10.1.1. Orilissa
  • 10.1.2. Myfembree/Ryeqo
  • 10.1.3. Others
• 10.2. Market Analysis, Insights and Forecast - By Drug Class
  • 10.2.1. GnRH Antagonists
  • 10.2.2. GnRH Agonists
  • 10.2.3. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Oral
  • 10.3.2. Others
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2026)
• 11.2. Company Profiles (Overview, Products, SWOT Analysis, Recent Developments, Strategies, Financials (Based on Availability))
  • 11.2.1. Gesynta Pharma AB
  • 11.2.2. AbbVie Inc.
  • 11.2.3. Pfizer Inc.
  • 11.2.4. Organon group of companies.
  • 11.2.5. Bayer AG
  • 11.2.6. AstraZeneca
  • 11.2.7. Sumitomo Pharma Co., Ltd.